行业周报 信贷需求仍偏弱，三家银行半年报发布 银行业周报 (2024.08.12-2024.08.18) 2024 年 08 月 18 日 核心观点 。 银行板块表现略优于市场：本周沪深 300 指数上涨 0.42%，银行板块上涨 2.66%。细分板块来看，国有行、股份行、城商行、农商行分别上涨 4.29%、 2.32%、1.4%、1.84%。个股方面，中信银行（+6.2%）、交通银行（+5.6%）、 邮储银行（+4.86%）、建设银行（+4.79%）、中国银行（+3.89%）上涨。截 至 8 月 16 日，银行板块 PB 为 0.62 倍，股息率为 5.13%。 o 央行发布 7 月金融数据：（1）社融规模同比多增，增速略有回升。7 月新增 社融 7708 亿元，同比多增 2342 亿元；截至 7 月末，社融存量 395.72 万亿 元，同比增长 8.19%。（2）信贷"挤水分"延续，政府债与企业债仍是社融 增长的核心驱动。7 月，人民币贷款减少 796 亿元，同比多减 1131 亿元，主 要受信贷"挤水分"、季节性因素以及需求偏弱影响。7月，新增政府债 6911 亿元，同比多增 2802 亿元；新增企业债 ...

Investment Rating - The report maintains a "Recommended" rating for Jiangsu Bank, indicating a positive outlook based on its strong performance and growth potential [2]. Core Insights - Jiangsu Bank's operating performance is stable and improving, with H1 2024 revenue and net profit reaching 41.625 billion yuan and 18.731 billion yuan, respectively, representing year-on-year growth of 7.16% and 10.05% [1]. - The bank's net interest income for H1 2024 was 27.656 billion yuan, showing a year-on-year increase of 1.76%, while the net interest margin stood at 1.90% [1]. - The bank's non-interest income reached 13.969 billion yuan, a year-on-year increase of 19.74%, driven by a recovery in intermediary business and high investment returns [1]. Summary by Sections Financial Performance - For H1 2024, Jiangsu Bank achieved operating revenue of 41.625 billion yuan and net profit attributable to shareholders of 18.731 billion yuan, with annualized ROE at 16.42% [1]. - The bank's total loans grew by 8.47% year-to-date, with corporate loans increasing by 17.81% [1]. Business Segments - Corporate loans showed strong growth, particularly in manufacturing, green financing, and inclusive small and micro loans, which increased by 21.23%, 22%, and 13.83%, respectively [1]. - Retail loans experienced a slight decline of 2.76%, with mortgage loans remaining stable and consumer loans being reduced [1]. Asset Quality - As of June 2024, the non-performing loan ratio was 0.89%, unchanged from the beginning of the year, indicating stable asset quality [2]. - The coverage ratio for provisions was 357.2%, reflecting strong risk mitigation capabilities [2]. Future Projections - The report forecasts operating revenue to reach 80.297 billion yuan in 2024, with a growth rate of 8.08% [5]. - Net profit attributable to shareholders is projected to be 31.659 billion yuan in 2024, with a growth rate of 10.12% [5].

Investment Rating - The report maintains a "Recommended" rating for the company [3][4]. Core Views - The company reported a revenue of 308 million yuan in the first half of 2024, representing an increase of 11.79% year-on-year, and achieved a net profit of 6 million yuan, reversing a loss of 1 million yuan in the same period last year [2]. - The company's overseas and 3D product performance showed significant growth, with overseas revenue increasing by 29.91% to 88 million yuan, accounting for 28.68% of total revenue, up from 24.72% in the previous year [2]. - The gross margin stabilized at 97.71%, up from 93.67% and 95.12% in the previous two quarters, although operating cash flow decreased by 36.96% to 150 million yuan [2][3]. Financial Performance Summary - The company expects revenues of 955.93 million yuan, 1.14492 billion yuan, and 1.39256 billion yuan for 2024, 2025, and 2026 respectively, with year-on-year growth rates of 15.51%, 19.77%, and 21.63% [4][6]. - The projected net profits for the same years are 69.78 million yuan, 81.77 million yuan, and 101.95 million yuan, with growth rates of 13.64%, 17.18%, and 24.67% respectively [4][6]. - The earnings per share (EPS) are expected to be 0.58 yuan, 0.67 yuan, and 0.84 yuan for 2024, 2025, and 2026, with corresponding price-to-earnings (PE) ratios of 109.65, 93.57, and 75.06 [4][6]. Product Development and Market Position - The company has made significant investments in R&D, leading to continuous upgrades in product technology, including enhancements in 2D CAD and 3D CAD products [3][6]. - The introduction of new features in ZWCAD 2025 and ZW3D 2025 has improved user experience and expanded the product's competitiveness in various industries, including high-end manufacturing [3][6].

2024-03-16䫌鰑閗閤┬假鯵气分ⲇ闌騣 낊ꯟ䉗㐙䝠缦┯甯㴼낊ꯟն 瞬汻煝疵 · ⪢槊㝕稝鰑☋ꏕ翞⽟間㷌 䉗㐙㸉耘臅⥈ꮴ䛉溸뀔劻ꄢ婢㎈䓛槏䙎 ⪢槊㝕稝鰑☋ꏕ翞⽟間㷌 2024 䌑 08 劓 17 傽 呦䖦間掾 | --- | --- | --- | |-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

利能力指标来看,商贸零售、公用事业行业中的央国企也值得关注。 毎日晨报 银河观点集萃 2024年8月19日 | --- | --- | --- | |-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------| ...

风险;市场情绪不稳定风险。 策略研究 · 港股周观察 港股迎来外围市场与中报业绩双重催化 港股市场周观察 核心观点: 2024 年 08 月 17 日 ● ● ● ● | --- | --- | --- | |-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

公司点评报告 · 医药行业 转型升级致利润承压、短期费用投入较高 2024 年中报业绩点评 核心观点 。 事件：2024 年 8 月 15 日，长春高新公布 2024 年半年报，实现营业收入约 66.39 亿元，同比增长 7.63%；归母净利润 17.20 亿元，同比下降 20.40%。 24Q2 实现营收 34.61 亿元，同比增长 2.10%；归母净利润 8.61 亿元，同比下 滑 33.94%。受地产公司结算增加成本、金赛药业转型调整管理架构等原因影 响，上半年归母净利润出现下滑。 。 金赛药业营收持平企稳。2024H1 子公司金赛药业实现收入 51.52 亿元，同 比增长 0.25%，主要由于长效产品放量，营收企稳；实现归母净利润 17.69 亿 元，同比降低 19.49%，主要由于金赛新 BU 管理架构调整导致的管理费用提 升，以及研发投入增加。长期来看，粉针、水针均集采中标，长效产品 PEG 实 现自产自用，同时出海业务呈现良好态势，我们预计生长激素收入和净利润有 望实现稳中有增。 o 金赛药业处于关键转型期，多个产品或有望明年上市。以生长激素为基石， 金賽药业向妇儿健康领域延伸，虽组人促卵泡激素 ...

Investment Rating - The report maintains a "Recommended" rating for the company [4]. Core Views - The company reported a revenue of 2.143 billion yuan for the first half of 2024, a year-on-year decrease of 12.70%, while the net profit attributable to shareholders was 178 million yuan, an increase of 8.05% [2][3]. - The automotive business is steadily developing, with project appointments continuing to expand, reflecting a strong growth trend in the automotive market, particularly in the new energy vehicle sector, which reached a market share of 35.2% in the first half of 2024 [2][3]. - Structural improvements have boosted gross margins, with the gross margin reaching 21.12%, up 3.19 percentage points year-on-year, and a net margin of 8.27%, up 1.53 percentage points year-on-year [2][3]. Summary by Sections Financial Performance - In Q2 2024, the company achieved a revenue of 1.058 billion yuan, a year-on-year decrease of 21.61%, while the net profit attributable to shareholders was 103 million yuan, an increase of 4.67% [2]. - The company’s sales gross margin for the first half of 2024 was 21.12%, with a net margin of 8.27% [2][3]. - The company’s expenses for sales, management, R&D, and financial costs were 4.09%, 4.70%, 3.99%, and -2.12% respectively, with management expenses increasing due to travel and depreciation costs [2]. Business Development - The automotive business is experiencing robust project appointments, including contracts with major clients such as Yanfeng and NIO, with total project amounts of approximately 75 million yuan and 143 million yuan respectively [3]. - The company is focusing on high-value lighting products and enhancing automation in production, which has led to improved profitability [2][3]. Future Outlook - The company is expected to achieve net profits of 417 million yuan, 466 million yuan, and 511 million yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 0.87 yuan, 0.98 yuan, and 1.07 yuan [3][8].

Investment Rating - The report maintains a "Recommend" rating for the company [3][4]. Core Viewpoints - The company reported Q2 2024 results that exceeded expectations, with a revenue of 20.965 billion yuan, a year-on-year increase of 2.84%, and a net profit attributable to shareholders of 1.696 billion yuan, up 18.29% year-on-year [2]. - The pharmaceutical industrial segment showed robust growth, achieving a revenue of 6.698 billion yuan in H1 2024, a 10.63% increase year-on-year, while the medical aesthetics business faced challenges due to global economic conditions [2][3]. - The company has a strong pipeline with 129 projects under research, including 86 innovative products and biosimilars, and has increased R&D investment by 10.34% to 1.110 billion yuan in H1 2024 [3][5]. Financial Performance Summary - For H1 2024, the company achieved a revenue of 20.965 billion yuan, with a net profit of 1.696 billion yuan, and a non-recurring net profit of 1.625 billion yuan, reflecting growth rates of 2.84%, 18.29%, and 13.85% respectively [2]. - The forecast for net profit attributable to shareholders for 2024-2026 is projected at 3.429 billion yuan, 3.995 billion yuan, and 4.606 billion yuan, with year-on-year growth rates of 20.78%, 16.52%, and 15.29% respectively [5][6]. - The company’s earnings per share (EPS) are expected to be 1.95 yuan, 2.28 yuan, and 2.63 yuan for 2024-2026, with corresponding price-to-earnings (PE) ratios of 15, 13, and 11 [5][6].

行业点评报告 · 机械设备行业 24 年第二批动车组高级修招标再超预期 核心观点 o 事件：8 月 15 日，国铁发布 2024 年第二批动车组高级修招标，此次招标三级 修 24 组、四级修 146.625 组、五级修 302 组，叠加今年１月份的第一次动车 组高级修招标（三级修 32组、四级修 121.625组、五级修 207 组），全年累 计招标三级修 56 组、四级修 268.25 组、五级修 509 组。 。 第二次动车组高级修招标数量再超预期。（1）从数量上来看，今年两次招 标五级修累计已达 509 组，超过历史最高动车组整车招标数量（2015 年 467 组），我们认为原因有三，一是疫情期间维修需求释放有所延后，二是部分修 程短的车型（2 型车和 380A）已进入第二轮五级修，三是疫情前动车组利用 率高维修时间提前, 14-16 年采购高峰期投运的动车组进入五级修。 (2) 从招 标车型来看，此次五级修中修程短的车型（2A 型车 80 组、380A 型车 51 组） 占比 43%，其他五级修占比高的车型为 380B（114 组）和 380D（31 组）， 采购高峰期在 2014-2016 年，表明 ...